Status:
COMPLETED
Nicotine Lozenge to Reduce Smokeless Tobacco Use
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborating Sponsors:
University of Minnesota
Conditions:
Tobacco Use Disorder
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has as many health risks associated with its use as cigarettes. While there are many treatment programs that focus on stopping to...
Detailed Description
Individuals who use ST are at risk for developing heart disease, stroke, high blood pressure, and cancer. Other long-term effects include tooth abrasion, gum recession, and loss of bone in the jaw. Ma...
Eligibility Criteria
Inclusion
- No interest in stopping ST use within 90 days of study entry
- Using ST at least 6 times a day in the 6 months prior to study entry
- Willing to use contraception throughout the study
Exclusion
- Current use of tobacco or nicotine products, other than ST
- Current unstable medical condition
- Use of any medication that may affect tobacco use or be affected by a reduction in tobacco use
- Meets DSM-IV diagnostic criteria for any psychiatric disorder or substance abuse disorder within 6 months of study entry
- Use of any psychotropic medication within 6 months of study entry
- Pregnant or breastfeeding
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00218283
Start Date
January 1 2005
End Date
June 1 2007
Last Update
January 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455